Plasma concentration--effect relationships for felodipine: a meta analysis
- PMID: 1385566
- DOI: 10.1038/clpt.1992.105
Plasma concentration--effect relationships for felodipine: a meta analysis
Abstract
The plasma concentration versus antihypertensive effect relationship for the calcium antagonist felodipine was investigated in 67 patients with hypertension and 21 healthy subjects by use of the Emax model. No consistent effect of felodipine on blood pressure was observed in the healthy subjects. In patients with hypertension the plasma drug concentration and blood pressure versus time curves mirrored each other, indicating a close relationship between concentration and effect. The maximum effect (Emax) model fitted the diastolic blood pressure data of most patients, but the model was less often applicable in patients with low initial diastolic blood pressure levels. The average Emax values and the plasma felodipine concentration needed to obtain 50% of Emax for the patients with hypertension were 29 mm Hg and 8 nmol/L, respectively. The Emax values increased with increasing initial diastolic blood pressure levels but were similar in patients with high and low plasma felodipine concentrations. Age had negligible influence on the antihypertensive response to felodipine when compensation was made for the plasma concentrations.
Similar articles
-
Felodipine pharmacokinetics and plasma concentration vs effect relationships.Blood Press Suppl. 1992;2:1-30. Blood Press Suppl. 1992. PMID: 1343111 Clinical Trial.
-
Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.J Clin Pharmacol. 1990 Nov;30(11):1020-30. doi: 10.1002/j.1552-4604.1990.tb03589.x. J Clin Pharmacol. 1990. PMID: 2243149
-
Felodipine population dose-response and concentration-response relationships in patients with essential hypertension.Clin Pharmacol Ther. 1995 May;57(5):569-81. doi: 10.1016/0009-9236(95)90042-X. Clin Pharmacol Ther. 1995. PMID: 7768080 Clinical Trial.
-
Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review.J Cardiovasc Pharmacol. 1990;15 Suppl 4:S50-6. doi: 10.1097/00005344-199015004-00017. J Cardiovasc Pharmacol. 1990. PMID: 1693728 Review.
-
Vascular selectivity of felodipine: clinical experience.J Cardiovasc Pharmacol. 1990;15 Suppl 4:S17-20. doi: 10.1097/00005344-199015004-00004. J Cardiovasc Pharmacol. 1990. PMID: 1693718 Review.
Cited by
-
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.Drugs. 1992 Aug;44(2):251-77. doi: 10.2165/00003495-199244020-00008. Drugs. 1992. PMID: 1382018 Review.
-
A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.Eur J Clin Pharmacol. 1993;45(5):425-30. doi: 10.1007/BF00315513. Eur J Clin Pharmacol. 1993. PMID: 8112371 Clinical Trial.
-
Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.Drugs Aging. 1997 Dec;11(6):470-9. doi: 10.2165/00002512-199711060-00006. Drugs Aging. 1997. PMID: 9413704 Review.
-
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.Clin Pharmacokinet. 2000 Jan;38(1):41-57. doi: 10.2165/00003088-200038010-00003. Clin Pharmacokinet. 2000. PMID: 10668858 Review.
-
A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.Pharmaceutics. 2022 Jul 15;14(7):1474. doi: 10.3390/pharmaceutics14071474. Pharmaceutics. 2022. PMID: 35890369 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical